BETWEENDevelopment and License Agreement • May 9th, 2007 • Insulet Corp • Surgical & medical instruments & apparatus • Delaware
ARTICLE 1 DEFINITIONSDevelopment and License Agreement • January 20th, 2005 • Algorx Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.4 DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 25th, 2002 • Aderis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 28th, 2006 • Innexus Biotechnology Inc • Pharmaceutical preparations • British Columbia
INNEXUS CORPORATION, a company incorporated under the laws of Washington State and having an office at 3405 172nd Street, #196, Arlington (Seattle), Washington, U.S.A., 98223
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This DEVELOPMENT AND LICENSE AGREEMENT (this “AGREEMENT”) is made as of February 13, 2009 (the “EFFECTIVE DATE”) by and between Robert One, LLC, having its principal place of business at 123 Blackberry Lane, Amherst, MA 01002 (“ROBERT”), and Eagle Pharmaceuticals, Inc. having its principal place of business at 470 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“EAGLE”). ROBERT and EAGLE may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • December 5th, 2007 • Entropic Communications Inc • Semiconductors & related devices • New York
This Development and License Agreement (the “Agreement”), effective as of September 15, 2002 (the “Effective Date”), is entered into by and between RF Magic, Inc., a Delaware corporation having a place of business at 10182 Telesis Court, 4th Floor, San Diego, California 92121-4777, U.S.A. (“RFM”) and STMicroelectronics N.V., with its registered office at WTC Schiphol Airport, Schiphol Boulevard 265, 1118 BH Schiphol Airport, Amsterdam, the Netherlands, acting through its Swiss Branch located at 39, Chemin du Champ des Filles, 1228 Plan-les-Ouates, Geneva, Switzerland (“ST”).
BACKGROUNDDevelopment and License Agreement • June 1st, 2005 • Us Global Nanospace Inc • Miscellaneous fabricated textile products • Pennsylvania
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • May 9th, 2018 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Development and License Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”) by and between Bayer HealthCare AG, a German corporation (“Bayer”), with its principal place of business at D-51369 Leverkusen, Germany, and ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA. Bayer and ImmunoGen are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties”.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • March 17th, 2016 • Advanced Emissions Solutions, Inc. • Miscellaneous chemical products • Delaware
This DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”) is made the 25 day of June, 2010 (“Effective Date”) by and between ADA-ES, Inc., a Colorado corporation (“ADA”) and Arch Coal, Inc., a Delaware corporation (“Arch Coal,” and together with ADA, the “parties”).
Development and licensing agreement for oral formulation of insulinDevelopment and License Agreement • January 31st, 2022 • New York
Emisphere and Novo Nordisk entered an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen® Technology.
DEVELOPMENT AND LICENSE AGREEMENT between GW PHARMA LTD and GW PHARMACEUTICALS PLC and OTSUKA PHARMACEUTICAL CO., LTD dated as of February 14, 2007Development and License Agreement • April 18th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 14, 2007, by and among GW PHARMA LTD, a company organized under the laws of England, having offices at Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom, on behalf of itself and its Affiliates (collectively, “GW Pharma”), GW PHARMACEUTICALS PLC, a company organized under the laws of England, having offices at Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom and OTSUKA PHARMACEUTICAL CO., LTD., a Japan corporation, having offices at 2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, 101-8535, Japan (“Otsuka”). GW Pharma and Otsuka may be referred to herein individually as a “Party” or collectively as the “Parties.”
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. SERVICES, DEVELOPMENT AND LICENSE AGREEMENT This Agreement made this 30th...Development and License Agreement • January 14th, 1999 • Healtheon Corp • Services-computer processing & data preparation • California
AMENDED DEVELOPMENT AND LICENSE AGREEMENT By and between ALMIRALL, S.A. and ASLAN PHARMACEUTICALS PTE. LTD. Dated: December 21, 2015Development and License Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
This AMENDED DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated as of December 21, 2015 (“Effective Date”), is entered by and between ALMIRALL, S.A. (“ALMIRALL”), a Spanish corporation having its principal offices at Ronda de General Mitre, 151, 08022 Barcelona, Spain, and ASLAN PHARMACEUTICALS Pte. Ltd. (“ASLAN”), a Singapore corporation having its principal offices at 10A Bukit Pasoh Road, Singapore 089824. ALMIRALL and ASLAN shall be referred to individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT GENENTECH, INC. AND SEATTLE GENETICS, INC.Development and License Agreement • March 6th, 2001 • Seattle Genetics Inc /Wa • Services-commercial physical & biological research • Washington
This Amended and Restated Development and License Agreement (the "Agreement") is made effective as of March 2, 2001 (the "Agreement") by and between Genentech, Inc. ("GNE"), a Delaware corporation with its principal office at 1 DNA Way, South San Francisco, California 94080 and Seattle Genetics, Inc. ("SG"), a Delaware corporation with its principal office at 22215 26th Avenue SE, Bothell, Washington 98021, each on behalf of itself and its Affiliates. GNE and SG are sometimes referred to herein individually as a "Party" and collectively as the "Parties," and references to "GNE" and "SG" shall include their respective Affiliates.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • February 13th, 2018 • California
This Development and License Agreement (“Agreement”) is entered into as of November , 2001 (the “Effective Date”) by and between ABC and XYZ maintaining its principal place of business.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 24th, 2013 • Pain Therapeutics Inc • Pharmaceutical preparations • California
BETWEENDevelopment and License Agreement • March 1st, 2007 • Valeant Pharmaceuticals International • Pharmaceutical preparations • New York
Licensing, research and development agreement for anti-HF antibody AV-299Development and License Agreement • September 23rd, 2022 • New York
Under the terms of the agreement, human dosing with SCH900105 (AV-299) triggers a $3.0 million milestone payment from Schering Plough to AVEO.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • June 14th, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 19th day of September, 2012 (the “Effective Date”), by and between Onconova Therapeutics, Inc., a company organized under the laws of the State of Delaware with its principal place of business at 375 Pheasant Run, Newtown, PA 18490 (“Onconova”) and Baxter Healthcare SA, a company organized under the laws of the Switzerland with its principal place of business at Thurgauerstrasse 130 8152 Glattpark (Opfikon) Switzerland (“Baxter”). Onconova and Baxter may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO THE DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • October 15th, 2004 • Trimeris Inc • Biological products, (no disgnostic substances)
This AMENDMENT TO THE DEVELOPMENT AND LICENSE AGREEMENT (“Amendment”) is executed on this 12th day of July 2004 to be effective the 5th day of January 2004, by and between Trimeris, Inc. (“Trimeris”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, “Roche”).
Development and License AgreementDevelopment and License Agreement • June 5th, 2020 • Titan Medical Inc • Surgical & medical instruments & apparatus • New York
This Development and License Agreement (“Agreement”), dated and effective as of June 3, 2020 (the “Effective Date”), is by and between, on the one hand, Covidien LP, a Delaware limited partnership having a place of business at 15 Hampshire Street, Mansfield, Massachusetts 02048 (“Medtronic”), and on the other hand, Titan Medical Inc., a corporation incorporated under the Laws of the Province of Ontario, Canada with offices located at 155 University Avenue, Suite 750, Toronto, Ontario, M5H 3B7, Canada (“Titan”).
FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
THIS FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the "Amendment") is dated as of November 19, 2004, which Amendment shall become effective as of the effective date of that certain Second Amendment to the Agreement (as defined below) (the "Effective Date"), by and between NPS Pharmaceuticals, Inc. ("NPS") and Amgen Inc. ("Amgen"). NPS and Amgen are referred to in this Amendment individually as a "Party" and collectively as the "Parties."
December 24, 2012 AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT Between INTELLIKINE LLC and INFINITY PHARMACEUTICALS, INC.Development and License Agreement • June 5th, 2023 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Development and License Agreement (“Agreement”) is made as of this 24th day of December, 2012 (the “Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Delaware and successor to Intellikine, Inc. (“Intellikine”), and Infinity Pharmaceuticals, Inc., a company organized and existing under the laws of the State of Delaware (“Infinity”). Intellikine and Infinity are each referred to individually as a “Party” and together as the “Parties”.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • January 18th, 2007 • Spectre Gaming Inc • Services-miscellaneous amusement & recreation • Nevada
This Development and License Agreement (“Agreement”) is entered into effective as of May 15, 2006, by and between Spectre Gaming, Inc., a Minnesota corporation and having a principal place of business at 14200 23rd Avenue N., Minneapolis, Minnesota 55447 (“Spectre”), and Global Gaming Group, Inc., a Nevada corporation and having a principal place of business at 3035 East Patrick Lane Suite 14, Las Vegas, Nevada 89120 (“G3”).
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • October 6th, 2014 • Virobay Inc • Pharmaceutical preparations • New York
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of January 4, 2012 (the “Effective Date”) by and between VIROBAY INC., a Delaware corporation with its principal place of business at 1490 O’Brien Drive, Suite G, Menlo Park, CA 94025, USA (“Virobay”), and LEO PHARMA A/S, a Danish private limited company with its principal place of business at 55, Industriparken, 2750 Ballerup, Denmark (“LEO”). Virobay and LEO are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • December 15th, 2006 • Optimer Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENT (the "Agreement") is entered into as of March 31, 2006 (the "Effective Date") by and between OPTIMER PHARMACEUTICALS INC., a Delaware corporation with its offices located at 10110 Sorrento Valley Road, Suite C, San Diego, California 92121 ("Optimer"), and CEMPRA PHARMACEUTICALS, INC., a Delaware corporation with its offices located at 170 Southport Drive, Suite 500, Morrisville, NC 27560. Optimer and Cempra may be referred to herein individually as a "Party" or collectively, as the "Parties."
EX-10.3 3 alks-20180331ex10345098f.htm EX-10.3 Execution Version A complete version of this Exhibit has been filed separately with the Securities and Exchange Commission pursuant to an application requesting confidential treatment pursuant to Rule...Development and License Agreement • May 5th, 2020 • Delaware
THIS THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the “Third Amendment”) is entered into effective as of March 20, 2018, (the “Third Amendment Effective Date”) between AMYLIN PHARMACEUTICALS, LLC, a Delaware limited liability corporation having a principal place of business at 9360 Towne Centre Drive, San Diego, CA 92121 (“Amylin”), and ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) having a registered address at Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”) who is the successor-in-interest to ALKERMES CONTROLLED THERAPEUTICS INC. II (“ACTII”). Amylin and APIL are referred to herein collectively as “Parties” and individually as a “Party”.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • February 3rd, 2014 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 26, 2013 (the “Effective Date”) by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 99 Hayden Avenue, Suite 500, Lexington, MA 02421, USA (“Concert”), and JAZZ PHARMACEUTICALS IRELAND LIMITED, an Irish company, with its principal place of business at Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland (“Jazz”). Concert and Jazz are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • August 7th, 2012 • Kalobios Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), is made effective as of May 11, 2004 (the “Effective Date”), by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with its registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland and having an office at 605 Third Avenue, 33rd Floor, New York, NY 10158, USA (“LICR”), and KALOBIOS PHARMACEUTICALS, INC., a Delaware corporation (“KaloBios”), having an address at 3427 Hillview Avenue, Palo Alto, CA 94304, USA. KaloBios and LICR may be referred to herein individually as a “Party” and collectively as “Parties.”
CO-DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICA, N.V. AND MINERVA NEUROSCIENCES, INC. DATED FEBRUARY 13, 2014Development and License Agreement • June 10th, 2014 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • New York
THIS CO-DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), executed as of February 13, 2014 (the “Execution Date”), is made by and between Janssen Pharmaceutica, N.V., a corporation organized and existing under the laws of Belgium, having its principal place of business is at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter “Janssen”), and Minerva Neurosciences, Inc., a corporation organized under the laws of the State of Delaware, having its principal place of business at 245 First Street, Cambridge, Massachusetts (hereinafter “Minerva”). Janssen and Minerva are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND LICENSE AGREEMENT BETWEEN MARKET FINDERS BROKERAGE, INC. AND DANIEL DAUGHERTYDevelopment and License Agreement • April 16th, 2013 • MamaMancini's Holdings, Inc. • Sausages & other prepared meat products • New Jersey
This Development and License Agreement (“Agreement”) is made as of January 1, 2009 between Daniel Daugherty (“Licensor”), an individual residing at 625 Mountain Drive, South Orange, NJ 07079; and Market Finders Brokerage, Inc (“Licensee”), a New Jersey corporation with its principal place of business at 627 Inwood Lane, South Orange, NJ 07079.
BY AND BETWEEN GILEAD SCIENCES, INC. AND F. HOFFMANN-LA ROCHE LTD AND HOFFMANN- LA ROCHE INC.Development and License Agreement • February 25th, 1997 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
UNIVERSAL DISPLAY CORPORATION(TM) [GRAPHIC OMITTED] March 30, 2005 VIA FACSIMILE AND OVERNIGHT MAIL Mr. Richard C. Elias Vice President - Optical Products PPG Industries, Inc. 440 College Park Drive Monroeville, PA 15146 RE: AMENDMENT #6 TO THE...Development and License Agreement • July 19th, 2005 • Universal Display Corp \Pa\ • Computer terminals
DEVELOPMENT AND LICENSE AGREEMENT BETWEEN IMMUNOCORE LIMITED AND ELI LILLY AND COMPANYDevelopment and License Agreement • January 15th, 2021 • Immunocore LTD • Biological products, (no disgnostic substances) • England and Wales
Capitalized terms used in this Agreement, whether used in the singular or plural, shall have the meanings set forth below or elsewhere herein, unless otherwise specifically indicated herein.
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
This DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”), effective as of November 9, 2017 (the “Effective Date”), is made by and between CureVac AG, a German stock corporation organized under the laws of Germany, having its principal place of business at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”), and CRISPR Therapeutics AG, a Swiss corporation organized under the laws of Switzerland (“CRISPR”), having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland. CureVac and CRISPR are each sometimes referred to herein as a “Party” and collectively as the “Parties.”
